{"id":"tqb2868-injection","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Unfortunately, there is limited information available on the exact mechanism of action of TQB2868 injection.","oneSentence":"TQB2868 injection's mechanism is not publicly available.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:39:31.280Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Phase 3 for TQB2868 injection is not publicly available."}]},"trialDetails":[{"nctId":"NCT07165951","phase":"PHASE3","title":"Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)","status":"RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2025-12-02","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":566},{"nctId":"NCT06767813","phase":"PHASE2","title":"Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2024-03-19","conditions":"Pancreatic Neoplasms","enrollment":80},{"nctId":"NCT06441019","phase":"PHASE2","title":"Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-07-01","conditions":"Hepatocellular Carcinoma，Bispecific Antibodies, HAIC, Ramucirumab","enrollment":42},{"nctId":"NCT05998941","phase":"PHASE2","title":"A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer","status":"WITHDRAWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-08","conditions":"Cervical Cancer","enrollment":""},{"nctId":"NCT05198505","phase":"PHASE1","title":"Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2022-04-27","conditions":"Advanced Malignant Tumor","enrollment":280}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":595852,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TQB2868 injection","genericName":"TQB2868 injection","companyName":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-nanjing-shunxin-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TQB2868 injection is being studied in clinical trials for the treatment of various types of cancer, including cervical cancer, metastatic pancreatic ductal adenocarcinoma, and hepatocellular carcinoma. It is being investigated in combination with platinum-based chemotherapy and possibly other treatments, such as bevacizumab, in the first-line treatment of these cancers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}